Christopher Reyes, Founder and CEO of Bloom Science, joins a panel of experts to explore the Science of the Gut-Brain Axis 

SAN DIEGO, Calif., August 5, 2024 —Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that CEO Christopher Reyes will join a panel of entrepreneurs and researchers as they discuss the complexities of the gut microbiome and its profound impact on mental health and overall well-being.

Gut Feelings: Exploring the Gut-Brain Connection Lecture
Tue, Aug 6; 6:30P – 8:00P
The Battery SF

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.